Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 4/20 | 0.75 |
| ▸ | CES1 | P23141 | 4/20 | 0.75 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.68 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.64 |
| ▸ | PPARG | P37231 | 7/20 | 0.64 |
| ▸ | PPARD | Q03181 | 7/20 | 0.64 |
| ▸ | PPARA | Q07869 | 7/20 | 0.64 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.64 |
| ▸ | TSHR | P16473 | 4/20 | 0.64 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | TLR2 | O60603 | 2/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.64 |
| ▸ | FABP4 | P15090 | 2/20 | 0.64 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.64 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | ESR1 | P03372 | 1/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.64 |
| ▸ | PDE4A | P27815 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL233056 | 1.00 | CES2 (0.75) | CES2CES1HAO1GPR84PPARG | |
| SCHEMBL10961549 | 1.00 | CES2 (0.75) | CES2CES1HAO1GPR84PPARG | |
| SCHEMBL8741844 | 1.00 | CES2 (0.75) | CES2CES1HAO1GPR84PPARG | |
| SCHEMBL17315852 | 1.00 | CES2 (0.75) | CES2CES1HAO1GPR84PPARG | |
| SCHEMBL3016254 | 1.00 | CES2 (0.75) | CES2CES1HAO1GPR84PPARG | |
| SCHEMBL284705 | 1.00 | CES2 (0.75) | CES2CES1HAO1GPR84PPARG | |
| SCHEMBL337998 | 1.00 | CES2 (0.75) | CES2CES1HAO1GPR84PPARG | |
| SCHEMBL337341 | 1.00 | CES2 (0.75) | CES2CES1HAO1GPR84PPARG | |
| SCHEMBL6817517 | 1.00 | CES2 (0.75) | CES2CES1HAO1GPR84PPARG | |
| SCHEMBL174462 | 1.00 | CES2 (0.75) | CES2CES1HAO1GPR84PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3488000-A1 | METHODS AND MATERIALS FOR BIOSYNTHESIZING MULTIFUNCTIONAL, MULTIVARIATE MOLECULES VIA CARBON CHAIN MODIFICATION | INVISTA Textiles (U.K.) Limited (GB) | 2019-05-29 | — | — | EP | claimed |
| WO-2018022633-A1 | METHODS AND MATERIALS FOR BIOSYNTHESIZING MULTIFUNCTIONAL, MULTIVARIATE MOLECULES VIA CARBON CHAIN MODIFICATION | INVISTA TEXTILES (U.K.) LIMITED (GB) | 2018-02-01 | — | — | WO | claimed |
| US-12122994-B2 | Methods for fermentative production of massoia lactone | TEMASEK LIFE SCIENCES LABORATORY LIMITED (SG) | 2024-10-22 | — | — | US | disclosed |
| US-20230365915-A1 | METHODS FOR FERMENTATIVE PRODUCTION OF MASSOIA LACTONE | TEMASEK LIFE SCIENCES LABORATORY LIMITED (SG) | 2023-11-16 | — | — | US | disclosed |
| US-11692116-B2 | Phase change material composition and method of preparation thereof | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-07-04 | — | — | US | disclosed |
| WO-2023089522-A1 | NOVEL LIPIDS FOR DELIVERY OF NUCLEIC ACID SEGMENTS | ASTRAZENECA AB (SE) | 2023-05-25 | — | — | WO | disclosed |
| US-11639492-B2 | Methods for fermentative production of massoia lactone | TEMASEK LIFE SCIENCES LABORATORY LIMITED (SG) | 2023-05-02 | — | — | US | disclosed |
| EP-3337889-B1 | METHODS FOR FERMENTATIVE PRODUCTION OF MASSOIA LACTONE | TEMASEK LIFE SCIENCES LABORATORY LTD (SG) | 2023-04-26 | — | — | EP | disclosed |
| US-11351268-B2 | FGF21 C-terminal peptide optimization | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2022-06-07 | — | — | US | disclosed |
| EP-3488000-A1 | METHODS AND MATERIALS FOR BIOSYNTHESIZING MULTIFUNCTIONAL, MULTIVARIATE MOLECULES VIA CARBON CHAIN MODIFICATION | INVISTA Textiles (U.K.) Limited (GB) | 2019-05-29 | — | — | EP | disclosed |
| CN-108611349-A | antisense nucleic acid | 日本新药株式会社 | 2018-10-02 | — | — | CN | disclosed |
| WO-2018022633-A1 | METHODS AND MATERIALS FOR BIOSYNTHESIZING MULTIFUNCTIONAL, MULTIVARIATE MOLECULES VIA CARBON CHAIN MODIFICATION | INVISTA TEXTILES (U.K.) LIMITED (GB) | 2018-02-01 | — | — | WO | disclosed |
| EP-2070919-B1 | SPIROQUINONE COMPOUND AND PHARMACEUTICAL COMPOSITION | HYKES LAB LLC (JP) | 2012-10-10 | — | — | EP | disclosed |
| US-8119686-B2 | Spiroquinone compound and pharmaceutical composition | HYKES LABORATORIES LLC (JP) | 2012-02-21 | — | — | US | disclosed |
| US-20100056613-A1 | SPIROQUINONE COMPOUND AND PHARMACEUTICAL COMPOSITION | HYKES LABORATORIES LLC (JP) | 2010-03-04 | — | — | US | disclosed |
| EP-2070919-A1 | SPIROQUINONE COMPOUND AND PHARMACEUTICAL COMPOSITION | Hykes Laboratories LLC (JP) | 2009-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056613-A1 | SPIROQUINONE COMPOUND AND PHARMACEUTICAL COMPOSITION | NR1H2, NR1H3, APOB | CES2 1621/4885CES1 226/4885HAO1 3758/4885 |
| US-11351268-B2 | FGF21 C-terminal peptide optimization | FGF23, FGFR1, FGFR3 | CES2 3550/4885CES1 490/4885HAO1 3689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.